Catalyst Funds Management Pty Ltd Has $2.21 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Catalyst Funds Management Pty Ltd grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1,962.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,500 shares of the life sciences company’s stock after buying an additional 15,700 shares during the quarter. Catalyst Funds Management Pty Ltd’s holdings in Illumina were worth $2,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in Illumina during the fourth quarter valued at approximately $32,000. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Illumina during the 4th quarter valued at $45,000. Assetmark Inc. lifted its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $85.60 on Friday. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66. The firm has a market capitalization of $13.56 billion, a PE ratio of -11.15, a PEG ratio of 1.60 and a beta of 1.17. The business’s 50 day moving average is $113.52 and its 200-day moving average is $129.88. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ILMN. Stephens reaffirmed an “overweight” rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday. Royal Bank of Canada reduced their target price on Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday. Barclays reiterated an “underweight” rating on shares of Illumina in a report on Tuesday. Guggenheim lowered their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Citigroup decreased their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.